Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients

Abstract

AIMTo evaluate the clinical value and efficiency of trans-arterial chemoperfusion (TACP) in patients with liver metastases from breast cancer (BC) and colorectal cancer (CRC).METHODSWe treated 36 patients with liver metastases of BC (n = 19, 19 females) and CRC (n = 17; 8 females, 9 males) with repeated TACP. The treatment interval was 4 wk. TACP was performed with gemcitabine (1000 mg/m2) and mitomycin (10 mg/m2), administered within 1 h after positioning the catheter tip in the hepatic artery. Before treatment, the size, location, tumour volume, vascularization and number of liver tumours were evaluated using magnetic resonance imaging (MRI). Tumour response was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines.RESULTSTACP using gemcitabine and mitomycin for metastases from CRC and BC was performed without any serious side effects. The follow-up MRI showed a therapeutic response in 84.2% of the BC patients - stable disease 47.4% and partial response 36.8%. A progression was seen in 15.8%. CRC patients showed a therapeutic response in 52.9% of cases. A progression of the disease was documented in 47.1% of the patients with CRC. These data show that TACP in patients with liver metastases of BC leads to a significantly better therapeutic response compared with CRC patients (P = 0.042). The median survival time was 13.2 mo for the BC patients, which is significantly longer than for CRC patients at 9.3 mo (P = 0.001).CONCLUSIONTACP for liver metastases of BC appears to be a safe and effective palliative treatment with improved outcomes in comparison to patients with CRC.

Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis

“…Moreover, liver metastases are frequently observed in BCa patients [60]. Available treatments for human patients, however, are limited and only palliative [61]. In this study, BCa-related liver metastases were recapitulated and significantly reduced by the CPT-containing pSiNP treatment.…”

Effects of Combination of Cisplatin and Paclitaxel Chemotherapy on Tumor Mass in Nasopharyngeal Carcinoma Patients at Dr. Wahidin Sudirohusodo Hospital Makassar with the RECIST Method

“…Inclusion criteria were NPC patients who had undergone complete chemotherapy (from chemotherapy I to chemotherapy VI to the 21-day schedule) without changing chemotherapy regimens, and complete patient medical record data including sex, age, stage, histopathology, chemotherapy regimen used, tumor mass size before chemotherapy, and tumor mass size after chemotherapy. The age group used is a 10-year interval (Yusuf and Foris, 2020), and the patient stage group uses the tumor node metastasis (TNM) classification system according to the 8th edition of AJCC, The tumor mass reduction group based on the type of treatment was classified by RECIST (Respon Evaluation Criteria in Solid Tumor) (Rouh et al, 2017). Furthermore, the data were analyzed by Chi-Square Test to determine whether the type of chemotherapy treatment affects the tumor…”

Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review

“…There were an astonishing 26 complete responders (7.2%); 132 partial responders (38.1%); 133 patients (36.7%) with stable disease; and 58 patients (16%) had disease progression. mOS data from six studies (11,(48)(49)(50)(51)(52) showed a median of 19.6 months (4.6-32 months). One-year survival data was provided in four studies (12,47,49,51) ranging from 32 to 88.8%.…”